BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
296.04
-1.30 (-0.44%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close297.34
Open298.00
Bid0.00 x 1000
Ask0.00 x 900
Day's Range295.00 - 298.38
52 Week Range249.17 - 370.57
Volume1,054,714
Avg. Volume1,696,646
Market Cap62.467B
Beta1.16
PE Ratio (TTM)21.16
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs
    Investor's Business Daily4 days ago

    Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs

    PTC Therapeutics spiked Wednesday after an analyst suggested it and Roche could rout Biogen and Ionis Pharmaceuticals in treating spinal muscular atrophy.

  • 5 Experimental New Drugs That Could Be Worth $47 Billion
    Motley Fool5 days ago

    5 Experimental New Drugs That Could Be Worth $47 Billion

    Optimism for these research and development projects is higher than all the rest.

  • Biogen and Ionis Crash on PTC Therapeutics’ Promising Data
    Market Realist6 days ago

    Biogen and Ionis Crash on PTC Therapeutics’ Promising Data

    Biogen and Ionis Crash on PTC Therapeutics' Promising DataPTC Therapeutics presented positive data on its SMA drug under trial

  • PTC Therapeutics' Spinal Muscular Atrophy Study Successful
    Zacks6 days ago

    PTC Therapeutics' Spinal Muscular Atrophy Study Successful

    PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.

  • S&P 500’s Top Losses: Why Biogen Declined
    Market Realist6 days ago

    S&P 500’s Top Losses: Why Biogen Declined

    The S&P 500’s top losses on June 18 were: Biogen (BIIB) declined 5.2%. Comcast Corp A (CMCSA) declined 3.8%. AmerisourceBergen (ABC) declined 3.5%. Intel (INTC) declined 3.4%. CVS (CVS) declined 3.4%. Biogen    

  • Barrons.com6 days ago

    After the Bell: Dow Drops 100 Points, but Tariffs Don't Matter…Yet

    The Dow Jones Industrial Average dropped more than 100 points today but the loss wasn't nearly as bad as it could have been. For the past two days, the Dow Jones Industrial Average has started off with sizable selloffs, only to rally back. The S&P 500, meanwhile, has barely finished down on those days, and today the Nasdaq Composite didn't even drop.

  • Why Biogen, Baytex Energy, and Catalyst Biosciences Slumped Today
    Motley Fool6 days ago

    Why Biogen, Baytex Energy, and Catalyst Biosciences Slumped Today

    Find out why good news elsewhere hurt one of these stocks.

  • Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle
    Motley Fool7 days ago

    Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle

    Investors value a new round of data for PTC's spinal muscular atrophy drug.

  • CNBC7 days ago

    Biogen plunges after rival drug for spinal muscular atrophy shows promise

    Biogen tumbled 6 percent on Monday, after a rival drugmaker reported its experimental drug for spinal muscular atrophy helped a majority of babies who received it. Biogen has a few new drugs in the pipeline, including one that could help the company defend its leadership in MS drug therapy, but these are at least two years away reaching the market. Biogen BIIB tumbled as much as 6 percent on Monday, after a rival drugmaker reported its experimental drug for spinal muscular atrophy helped a majority of babies who received it.

  • Bloomberg7 days ago

    PTC Therapeutics Up Most Since 2016 on Rare-Disease Drug Results

    PTC Therapeutics Inc. shares rose to their highest price since August 2015 after the company said its experimental drug for spinal muscular atrophy helped the vast majority of babies who got the treatment. Over the weekend the company reported that after 182 days of treatment, 91 percent of babies on the drug improved more than four points on a scale that measures motor milestone developments in patients with a form of spinal muscular atrophy, or SMA. Spinal muscular atrophy is a rare disease that progressively takes away people’s physical strength and their ability to walk, eat and breathe.

  • Stocks Slide; Intel Downgraded; JD.com Spikes On Google Deal
    Investor's Business Daily7 days ago

    Stocks Slide; Intel Downgraded; JD.com Spikes On Google Deal

    Stocks slid lower Monday as global markets remained rattled by the U.S.-China trade standoff. China stocks were highly active, however, led by JD.com.

  • Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
    Zacks10 days ago

    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

  • Should You Be Tempted To Buy Biogen Inc (NASDAQ:BIIB) Because Of Its PE Ratio?
    Simply Wall St.10 days ago

    Should You Be Tempted To Buy Biogen Inc (NASDAQ:BIIB) Because Of Its PE Ratio?

    Biogen Inc (NASDAQ:BIIB) is trading with a trailing P/E of 21.9x, which is lower than the industry average of 28.7x. While BIIB might seem like an attractive stock to buy,Read More...

  • Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod
    Zacks12 days ago

    Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

    Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.

  • Alzheimer's Research Stumbles Again: What's the Road Ahead?
    Zacks13 days ago

    Alzheimer's Research Stumbles Again: What's the Road Ahead?

    The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.

  • Financial Times13 days ago

    [$$] Alzheimer’s cure: a fading hope

    Alzheimer’s disease ruins lives. As people live longer, more lives will be ruined every passing year. The brain disorder has done just as much damage to the hopes of medical researchers. While some drugs ...

  • Barrons.com14 days ago

    Biogen Buys $625 Million in Ionis Stock

    Biogen (BIIB) completed a pact to collaborate with Ionis Pharmaceuticals (IONS), and bought 11.5 million Ionis shares for $625 million, paying $54.34 each. Biogen also invested $375 million as an upfront payment to Ionis to "jointly discover and develop novel antisense drugs for a broad range of neurological diseases," as stated in a press release. In total, Biogen laid out $1 billion in cash.

  • Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset
    Zacks17 days ago

    Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset

    Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit17 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • Biogen's head of late-stage trials leaves for Sarepta
    American City Business Journals18 days ago

    Biogen's head of late-stage trials leaves for Sarepta

    Gilmore O’Neill’s exit from Biogen comes at a particularly inopportune moment for the company, which is testing a potential Alzheimer’s treatment in late-stage studies.

  • MarketWatch18 days ago

    Biogen enters exclusive option agreement to acquire TMS' treatment for acute stroke

    Biogen Inc. said Thursday it has entered an exclusive option agreement with TMS Co. Ltd. to acquire its TMS-007 treatment for acute stroke. "TMS-007 is a plasminogen activator with a novel mechanism of action associated with breaking down blood clots, and is believed to inhibit local inflammation at the site of thrombosis," Biogen said in a statement. The drug has the potential to extend the treatment window compared with current thrombolytic agents, it said.

  • Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO
    Zacks19 days ago

    Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO

    The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.

  • Biogen Inc Stock Got an Upgrade, but Should You Listen?
    InvestorPlace21 days ago

    Biogen Inc Stock Got an Upgrade, but Should You Listen?

    Generally speaking, pharmaceuticals are experiencing a mixed year. After a promising start where Biogen shares closed out January up more than 8%, the momentum quickly collapsed. It wasn’t until the prior month that BIIB stock began to recover from its mess.

  • Better Buy: Biogen Inc. vs. Celgene
    Motley Fool22 days ago

    Better Buy: Biogen Inc. vs. Celgene

    Which of these beaten-down biotech stocks wins in a head-to-head match-up?

  • Investopedia24 days ago

    Biogen's Big Stock Rally May Fizzle

    Biogen Inc's ( BIIB) stock has rebounded sharply over the past few weeks, with the stock rising by over 14% since April 23. The stock has struggled in 2018, with shares down by nearly 20% from their highs in late January and for a good reason. Biogen shares have risen to a technical resistance level at $300 and have failed to rise above that resistance level.